Pivekimab sunirine (IMGN 632), an antibody-drug conjugate (ADC) that targets CD123, consists of a high-affinity CD123 antibody coupled with a cleavable linker and an indolinobenzodiazepine pseudodimer (IGN) payload. This compound is employed in the research of hematological malignancies [1] [2].

Pivekimab sunirine exhibits cytotoxicity in AML cell lines with an IC₅₀ ranging from 0.6 pM to 40 pM over an incubation period of 4-6 days [2]. Cell Viability Assay [2] was conducted on cell lines EOL-1, HNT-34, KASUMI-3, KG-1, KO52, MOLM-13, MV4-11, SHI-1, SKM-1, and UCSD-AML1 with concentrations approximately 0-1 nM.

Pivekimab sunirine（40-240 μg/kg，i.p.）在人体AML小鼠异种移植模型中引起肿瘤消退[2]。此外，Pivekimab sunirine（8和80 μg/kg，i.p.）能够延长播散性Molm-13异种移植模型小鼠的生存时间[2]。 动物模型：人AML异种移植模型[2]。剂量：40、80、240 μg/kg。给药途径：i.p.。结果：在240 μg/kg剂量下诱导完全且持久的肿瘤消退。